Drug Trial Radar · NCT07289763
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Dec 31, 2025
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Conditions
- Primary Membranous Nephropathy
Interventions
SHR-2173 injectionDrug
SHR-2173 injection, with a total of 8 administrations
SHR-2173 injectionDrug
SHR-2173 injection, with a total of 16 administrations
SHR-2173 injectionDrug
SHR-2173 injection , with a total of 32 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Week0, 2, 4, 8, 12,16, 20, 24, 28, 32, 36, 40, 48 52
- 12-lead ECGTime frame: Week4, 8, 12, 24, 28, 36, 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General hospital of eastern theater command
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.